Regeneron and Teva announce positive topline phase 3 fasinumab results
Regeneron and Teva announced positive topline results from a Phase 3, randomized, double-blind, placebo-controlled study of fasinumab in patients with chronic pain from osteoarthritis of the knee or hip. At the week 16 primary efficacy analysis, the study met both co-primary endpoints. August 16, 2018